newsfilter
← Latest News
GlobeNewswire·

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

SARASOTA, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biopharmaceutical company committed to developing novel therapies for neurological disorders, today provided a corporate update